{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:20:11Z","timestamp":1794277211474,"version":"4.9.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajog.2025.07.040","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:53:49Z","timestamp":1754430829000},"page":"617.e1-617.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7057-6580","authenticated-orcid":false,"given":"Oluwatosin","family":"Goje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkechi E.","family":"Azie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nyirjesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2025.07.040_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ajog.2025.07.040_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/DDDT.S339349","article-title":"Ibrexafungerp for the treatment of vulvovaginal candidiasis: design, development and place in therapy","volume":"17","author":"Phillips","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ajog.2025.07.040_bib3","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","article-title":"Global burden of recurrent vulvovaginal candidiasis: a systematic review","volume":"18","author":"Denning","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ajog.2025.07.040_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1477-7525-11-169","article-title":"Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA","volume":"11","author":"Aballea","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ajog.2025.07.040_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/20503121221115201","article-title":"Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis","volume":"10","author":"Neal","year":"2022","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.ajog.2025.07.040_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00404-019-05228-3","article-title":"Influence of recurrent vulvovaginal candidiasis on quality of life issues","volume":"300","author":"Fukazawa","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2025.07.040_bib7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajog.2025.07.040_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa033114","article-title":"Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis","volume":"351","author":"Sobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2025.07.040_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/myc.13582","article-title":"A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates","volume":"66","author":"Sobel","year":"2023","journal-title":"Mycoses"},{"key":"10.1016\/j.ajog.2025.07.040_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/jof4040121","article-title":"An update on the roles of non-albicans Candida species in vulvovaginitis","volume":"4","author":"Makanjuola","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.ajog.2025.07.040_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/LGT.0000000000000733","article-title":"Fluconazole-resistant Candida albicans vaginal infections at a referral center and treated with boric acid","volume":"27","author":"File","year":"2023","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2025.07.040_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/jwh.2022.0132","article-title":"Oral ibrexafungerp for vulvovaginal candidiasis treatment: an analysis of VANISH 303 and VANISH 306","volume":"32","author":"Goje","year":"2023","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.ajog.2025.07.040_bib13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4155\/fmc-2018-0465","article-title":"Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents","volume":"11","author":"Hasim","year":"2019","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ajog.2025.07.040_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves fks mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jimenez-Ortigosa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2025.07.040_bib15","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajog.2025.07.040_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 is fungicidal against Candida species in time-kill studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2025.07.040_bib17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ajog.2025.07.040_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02119-18","article-title":"SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats","volume":"63","author":"Wring","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2025.07.040_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00562-21","article-title":"In vitro pH activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida isolates from women with vulvovaginal candidiasis","volume":"65","author":"Sobel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2025.07.040_bib20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2025.07.040_bib22","series-title":"SCY-078 phase 2 study in moderate and severe vulvovaginal candidiasis (VVC) [abstract p1748]","author":"Roman","year":"2017"},{"key":"10.1016\/j.ajog.2025.07.040_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/jof6010027","article-title":"Vulvovaginal candidiasis: a current understanding and burning questions","volume":"6","author":"Willems","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.ajog.2025.07.040_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/microorganisms8020144","article-title":"Recurrent vulvovaginal candidiasis: an immunological perspective","volume":"8","author":"Rosati","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.ajog.2025.07.040_bib25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/LGT.0000000000000413","article-title":"Long-term outcomes of women with recurrent vulvovaginal candidiasis after a course of maintenance antifungal therapy","volume":"22","author":"Crouss","year":"2018","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2025.07.040_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/jof6030113","article-title":"Recurrent vulvovaginal candidosis and cluster analysis of clinical signs and symptoms: a laboratory-based investigation","volume":"6","author":"Ignjatovic","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.ajog.2025.07.040_bib27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/14656566.2018.1476490","article-title":"Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species","volume":"19","author":"Sobel","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajog.2025.07.040_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/myc.13248","article-title":"Guideline: vulvovaginal candidosis (AWMF 015\/072, level S2k)","volume":"64","author":"Farr","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.ajog.2025.07.040_bib29","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1067\/S0002-9378(03)00726-9","article-title":"Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine","volume":"189","author":"Sobel","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.07.040_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/sti.79.3.265-a","article-title":"Treatment of Candida glabrata using topical amphotericin B and flucytosine","volume":"79","author":"Shann","year":"2003","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.ajog.2025.07.040_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/sti.77.3.212","article-title":"Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections","volume":"77","author":"White","year":"2001","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.ajog.2025.07.040_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00562-21","article-title":"In vitro pH activity of ibrexafungerp against fluconazole-susceptible and - resistant Candida isolates from women with vulvovaginal candidiasis","volume":"65","author":"Sobel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2025.07.040_bib35","doi-asserted-by":"crossref","first-page":"e02611","DOI":"10.1128\/AAC.02611-18","article-title":"A novel 1,3-beta-d-glucan inhibitor, ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis","volume":"63","author":"Larkin","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937825005204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937825005204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:06:55Z","timestamp":1772827615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937825005204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0002937825005204"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2025.07.040","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2025.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}